Search

everythinglearnresearchcommunity

for

Search:↓

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

A Spanish doctor shared a video about Verteporfin for hair loss. The conversation mentions Minoxidil, finasteride, and RU58841 as treatments.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A user named "tresslessinseattle" receiving a mysterious package of Eucapil hair loss treatment, which they are considering in combination with Minoxidil and Finasteride treatments to boost the regrowth they have been seeing.

The user shared their bloodwork results showing DHT at 17 ng/dl and testosterone at 287 ng/dl, with a slight Vitamin D deficiency. They are seeking opinions on these levels and have an upcoming dermatologist appointment.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The conversation discusses using estradiol and its derivatives for hair loss without causing feminization. Users mention alternatives like alfatradiol, topical 17b-Estradiol, and DIM (Diindolylmethane).

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The conversation discusses using topical spironolactone for temple hair loss, alongside low-dose minoxidil and possibly PDRN injections, without finasteride or dutasteride. The user is skeptical about the injections due to cost and mild hair loss severity.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

A user's progress in hair regrowth after taking finasteride (1mg) every other day, and the replies to the post offering support, advice, and encouragement.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

Exosomes are being considered for hair regrowth after using finasteride and minoxidil, with skepticism about their effectiveness and high cost. Users discuss administration methods like injections and microneedling, but concerns about pricing and potential scams are prevalent.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

The conversation is about finding a reliable source to purchase Pyrilutamide that ships to the UK. There's also an openness to using RU58841 as an alternative.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.